Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The goals of this study are to evaluate the efficacy of JNJ-18038683 in an 8 week trial to
ameliorate the cognitive deficit and reduce residual depressive symptoms in 60 stable bipolar
outpatients receiving treatment for depression. JNJ-18038683 will be studied and compared
with placebo as adjunctive treatment to standard pharmacologic treatment for bipolar
disorder.